Floatz logo

ONC 206

World Health Organization (WHO) Grade III Glioma

Sabine Mueller, MD, PhDSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the World Health Organization (WHO) Grade III Glioma cohort.

Asset / SponsorPhaseRating
Sorafenib
Virginia Commonwealth University
Phase 2BB
Everolimus
Nationwide Children's Hospital
Phase 2B
Fycompa
Mayo Clinic
Phase 4B
Lomustine
M.D. Anderson Cancer Center
Phase 2B
THIOGUANINE ANHYDROUS
M.D. Anderson Cancer Center
Phase 2B

View all 38 →

Same molecule, other indications

ONC 206 is also rated in:

grade II meningiomaDormant
CC
Indicative ·
43 / 100
View asset →
ependymomaDormant
CC
Indicative ·
43 / 100
View asset →
central nervous system cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →